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Abstract
Background: Chagas disease constitutes an important public health threat in terms of morbidity and mortality in
the areas in the United States where immigrant populations from Latin America are conspicuous. We conducted a
survey to assess the prevalence of anti-T. cruzi antibody in Hispanic-surnamed patients seen at Parkland Memorial
Hospital in Dallas, Texas.
Findings: Five hundred serum specimens from Hispanic-surnamed patients were tested by a preliminary ELISA
method. On a subset of 50 sera confirmatory testing was also performed using an alternative ELISA, indirect
immunofluorescence, and TESA immunoblot. For 274 of 500 Hispanic-surnamed patients, we were able to ascertain
immigration status upon medical chart review. Of the 274 sera analyzed, one sample tested as positive for anti-T.
cruzi antibody by the preliminary ELISA, and by the three confirmatory methods.
Conclusions: The goal of this study is to increase the awareness of T. cruzi infection and Chagas disease in areas
where the Latin American immigrant communities are growing. Our study highlights the importance of testing for
Chagas disease in the populations most at risk, and the need for current data on the actual seroprevalence in areas
where such immigrant populations are conspicuous. Larger-scale epidemiologic surveys on Chagas disease in the
immigrant communities from Latin America are warranted.
Background
Chagas disease, also known as American trypanosomia-
sis, is an infection caused by the parasite Trypanosoma
cruzi. This parasite is usually transmitted to humans by
Triatominae insects as vectors. Transmission of the
infection also occurs transplacentally, via blood transfu-
sion, organ transplantation, laboratory incident, and
ingestion of triatomine-contaminated food or drink
[1-12]. Chagas disease has an acute stage, typically
asymptomatic or with mild symptoms (e.g., fever,
malaise, swelling at the site of inoculation, and lympha-
denopathy) during the first 6 to 8 weeks after infection.
This acute stage is often undetected and thus not trea-
ted. If not treated, Chagas disease becomes a chronic,
lifelong condition which can go undetected for several
decades in any given patient. The majority of infected
persons remain asymptomatic in the chronic indetermi-
nate phase (i.e., a prolonged period of clinically silent
infection that follows acute primary infection). However,
an estimated ~30% of infected individuals will have
onset of chronic symptomatic disease, usually decades
after the initial infection, with cardiac manifestations (e.
g., cardiomyopathy, arrhythmias, and sudden death) or
gastrointestinal involvement (e.g., megaesophagus and
megacolon) [2,13]. Currently available drugs for Chagas
disease require a prolonged course, pose a significant
risk of adverse effects, and require careful monitoring
[14]. Chagas disease is a major public health concern in
Latin America where 8-10 million persons are chroni-
cally infected [12]. Historically, it has been considered as
endemic mostly in the rural areas of Latin America [12],
and the prevalence rate of T. cruzi infection in the ende-
mic areas varies considerably from country to country in
Mexico, Central and South America. The epidemiology
of Chagas disease has been greatly modified in recent
times by urbanization and international migration
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any medium, provided the original work is properly cited.[15-20]. Unrecognized disease in the immigrant popula-
tions might lead to emerging health problems within the
areas in the United States where immigrant commu-
nities are growing. Prior infection with T. cruzi has been
previously documented in such populations by blood
donor screening and follow up [7,8,10-12]. Estimates of
T. cruzi antibody prevalence in the blood donor popula-
tion in the United States vary widely, reflecting geo-
graphic differences as well as a trend of steady increase
in prevalence as a result of conspicuous immigration
from the endemic areas of Latin America over the last
two decades [7,8,10-12]. In a recent survey by Tobler et
al.[11], the seroprevalence was found to be 0.03% among
blood donations in a region where 78% of the residents
were of Hispanic origin. However, any volunteer blood
donor population represents a highly selected group due
to the selection bias introduced by the “healthy blood
donor effect”, and the corresponding seroprevalence
rates are expected to underestimate the true prevalence
rate of anti-T. cruzi antibody in the Latin American
immigrant population. We conducted a survey to assess
the prevalence of anti-T. cruzi antibody in Hispanic-sur-
named patients seen at Parkland Memorial Hospital in
Dallas, Texas. The Dallas-Fort Worth metroplex area
includes a large immigrant population from Latin Amer-
ica. As the county hospital for Dallas, Texas, Parkland
Health & Hospital System serves the local Hispanic
communities, and the immigrant community originating




We obtained the serum samples from 500 Hispanic-sur-
named patients seen at Parkland Memorial Hospital
between November 2008 and May 2009. Specifically, we
used left-over serum samples collected from 500 Hispa-
nic-surnamed in-patients or out-patients that were sent
for testing to the immunology laboratory at Parkland
Memorial Hospital. That is, from serum samples col-
lected for diagnostic or treatment purposes (e.g., hepati-
tis serology or other infectious disease serology) and
only after such testing for diagnostic and treatment pur-
poses had been performed. For each of the 500 Hispa-
nic-surnamed patients from which a serum sample was
obtained, the electronic medical record was reviewed,
and any evidence of immigration status from Latin
America was noted. Specifically, we searched the medi-
cal record for notations such as “I m m i g r a n tf r o mL a t i n
America” or “Spanish-speaking only” as evidence of
their immigration status from Latin America. This is an
incomplete index of the immigrant status of our patient
population because it is not the hospital’s policy to
enquire regarding this issue.
Ethical consideration
The study was reviewed and approved by the Institu-
tional Review Board of University of Texas Southwes-
tern and by the Institutional Review Board of Parkland
Memorial Hospital. A waiver of informed consent of the
subjects included in the study was obtained from the
IRB for the purpose of this epidemiologic survey. Left-
overs from serum samples collected solely for non-
research purposes such as diagnosis and treatment were
used in this study. In the clinical immunology labora-
tory, upon selection of the Latin American-surnamed
patients to include in the study, the left-over serum
sample from such patients was transferred to a new
tube which was not labeled with patient identifiers. A
non-identifiable code was assigned to each left-over
sample obtained for the study so that no direct link to a
specific patient was possible.
Serologic testing for Chagas disease
Parkland Memorial Hospital clinical immunology
laboratory was requested to save all left-over serum spe-
cimens collected for diagnostic and/or treatment pur-
poses from in-patients and out-patients from the date of
IRB approval until May 2009. The serum was trans-
ferred to a new tube and was stored at - 70 C until use.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (Hemagen Chagas’
Kit - EIA Method; Hemagen Diagnostics, Inc, Columbia,
MD) was carried out according to the manufacturer’s
protocol on all 500 serum samples included in the
study. Absorbance was measured spectrophotometrically
at 450 nm. Positive and negative controls were included
in duplicate in each run, and yielded the expected
results.
Confirmatory testing for Chagas disease
Of the 500 serum samples included in the study and
tested by EIA method using the Hemagen Chagas’ kit as
discussed above, confirmatory testing was carried out on
a subset of 50 sera (see Results for selection criteria) at
the Centers for Disease Control and Prevention (CDC)
in the Parasitic Diseases Branch Laboratory. The confir-
matory assays used were Chagatest - ELISA Recombi-
nante v 3.0 (Wiener Laboratorios, Rosario, Argentina),
indirect immunofluorescence testing (IIF) [21], and
finally an Immunoblot assay using trypomastigote
excreted-secreted antigens (TESA-blot) [22]. For each of
the three confirmatory assays, positive and negative con-
trols were included in duplicate, and yielded the
expected results. The TESA-blot is performed using
excreted-secreted antigens that are spontaneously
released by the trypomastigote form into the culture
medium, and used in an immunoblot format for the
detection of anti-T. cruzi antibody in infected indivi-
duals. Briefly, the TESA immunoblot technique is a
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excreted-secreted antigens ("TESA”) are separated using
gel electrophoresis and then transferred to a nitrocellu-
lose membrane. The anti-T. cruzi antibody from the
serum of an infected patient will bind to the immobi-
lized antigen, and the antibody-antigen reaction is
detected exploiting an EIA-like enzymatic reaction that
yields a colored end-product.
Results
We initially tested 500 serum specimens from Hispanic-
surnamed patients seen at Parkland using the Hemagen
ELISA kit. Of these 500 sera, 428 were obtained from
men, and 72 were obtained from women. Age ranged
from 13 to 92 years, with a median age of 44 years. Of
the 500 sera, one sample tested as positive for anti-T.
cruzi antibody by Hemagen ELISA. For 274 of 500 His-
panic-surnamed patients, we were able to ascertain
immigration status upon medical chart review. Specifi-
cally the electronic medical record of these 274 Hispa-
nic-surnamed patients contained evidence of
immigration status from Latin America. Of these 274
sera, 231 were obtained from men, 43 were obtained
from women, and median age was 47 years. This set of
274 sera included the one sample that tested as positive
for anti-T. cruzi antibody by Hemagen ELISA, as
reported above. For the remaining 226 of these 500 sub-
jects, upon chart review, there was no evidence regard-
ing immigration status from Latin America. None of
these 226 tested as positive for anti-T. cruzi antibody by
Hemagen ELISA. We excluded from our analysis results
from the 226 patients for whom no evidence was found
regarding their immigration status. The subset of 50
samples sent to CDC for confirmatory testing included
the one sample that tested as positive by Hemagen,
along with other 49 randomly selected samples. The
confirmatory testing on this preliminary positive serum
yielded a positive result also using the Wiener recombi-
nant EIA method, as well as by IIF and TESA immuno-
blot. Of the remaining 49 randomly selected serum
samples sent to CDC for confirmatory testing, one addi-
tional sample yielded a result close to the cutoff value
for the ELISA Wiener Recombinante (OD value 0.453,
cutoff OD level 0.40) but negative on the other two
tests, IIF and TESA immunoblot. According to the
WHO guidelines for the laboratory diagnosis of Chagas
disease [1], different algorithms should be used for the
diagnosis of T. cruzi infection depending on the specific
purpose for laboratory testing. That is, two tests should
be used to confirm a clinical suspicion of Chagas disease
in a given patient, and a third test should be performed
if the results of the two tests are not concordant. For
the purpose of an epidemiologic survey or for blood
donor screening, a single test can be used, given the
excellent sensitivity of currently available assays. In this
survey, given the availability at the CDC of a variety of
assays for confirmatory testing, seropositivity results
from the concordant positive result of all the four test-
ing methodologies employed, exceeding even the most
stringent WHO criteria and testing algorithm aimed at
maximizing the specificity for the clinical diagnosis of
Chagas disease. Our survey resulted in a seroprevalence
of 0.4% (1/274) (95% CI 0%, 1.08%) among Hispanic-
surnamed patients selected for inclusion in this survey
analysis.
Discussion
The estimated 0.4% seroprevalence is derived from test-
ing of a convenience sample of left-over serum samples
from patients who had diagnostic testing done for pur-
poses unrelated to Chagas disease. A drawback of this
study is given by the limited subset of samples on which
the additional confirmatory testing was performed.
Another limitation of this study is possible misclassifica-
tion of immigration status for individuals who were
truly immigrants but did not have that noted in their
medical records. However, 0.4% seroprevalence is com-
parable to the estimated prevalence of Chagas disease in
some areas of Mexico, based on blood donor screening
results, and the testing criteria for seropositivity in this
study were more rigorous than most [1,23]. Given the
natural history of Chagas disease and the limitations of
currently available treatments, early detection and diag-
nosis are of paramount importance. Low-level, intermit-
tent parasitemia in the chronic indeterminate phase
constitutes a public health hazard not only because of
the potential for transmission through blood donation,
or organ and bone marrow donation but also because of
possible congenital transmission. Chronic infection can
remain undetected during the reproductive life of
women emigrated from endemic areas, putting their off-
spring at risk. Moreover, congenital transmission can be
multi-generational, as a US-born infected mother of
Hispanic descent who acquired the infection congeni-
tally from her mother may potentially transmit T. cruzi
to her offspring transplacentally. Health care providers
are even less likely to suspect congenital Chagas disease
in the offspring of a US-born Hispanic woman. Public
health officials and health care providers should antici-
pate an increased prevalence and incidence of congenital
Chagas disease within areas where Latin American
("Hispanic”) populations are growing.
Conclusions
Chagas disease has traditionally been considered as an
important public health issue in Latin American coun-
tries. However, the epidemiology of Chagas disease has
been changing in recent times mostly as a consequence
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America. Chagas disease constitutes an important public
health threat in terms of morbidity and mortality in
areas in the United States where immigrant populations
from Latin America are significant. Awareness of the
actual prevalence of T. cruzi infection in the immigrants
from Latin America is of paramount importance. Esti-
mates of T. cruzi antibody prevalence in the blood
donor population in the United States [7,8,10-12] most
likely do not reflect the true seroprevalence rates in the
Latin American immigrant population, as discussed
above. Current estimates of t h ep r e v a l e n c eo fC h a g a s
disease in the Hispanic immigrant communities living in
the US are based on demographic data, and not on
actual seroprevalence data obtained from testing on the
immigrant populations at risk. Our study highlights the
importance of testing for Chagas disease in the popula-
tions most at risk, and the need for current data on the
actual seroprevalence in areas where such immigrant
populations are growing. Larger-scale epidemiologic sur-
veys on Chagas disease in the immigrant communities
from Latin America are warranted.
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